Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (13617)
All Articles published online
|
Publishing Process of This Article
|
Apr 28, 2020 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol 2020; 26(16): 1861-1878 [PMID: 32390698 DOI: 10.3748/wjg.v26.i16.1861] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i16/1861.htm |
| Number | Citing Articles |
| 1 |
Zhao-Chun Chi. Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases. World Chinese Journal of Digestology 2022; 30(18): 783 doi: 10.11569/wcjd.v30.i18.783
|
| 2 |
Jingqi Liu, Yang Song, Ye Wang, Huashan Hong. Vitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease. Expert Opinion on Therapeutic Targets 2023; 27(11): 1145 doi: 10.1080/14728222.2023.2274099
|
| 3 |
Ziyan Pan, Saleh A. Alqahtani, Mohammed Eslam. MAFLD and chronic kidney disease: two sides of the same coin?. Hepatology International 2023; 17(3): 519 doi: 10.1007/s12072-023-10526-9
|
| 4 |
Eleni-Myrto Trifylli, Anastasios G. Kriebardis, Evangelos Koustas, Nikolaos Papadopoulos, Melanie Deutsch, Georgios Aloizos, Sotirios P. Fortis, Effie G. Papageorgiou, Ariadne Tsagarakis, Spilios Manolakopoulos. The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH—Future Horizons in NASH Management. International Journal of Molecular Sciences 2022; 23(20): 12185 doi: 10.3390/ijms232012185
|
| 5 |
Yu-Yao Mo, Yu-Xin Han, Shi-Na Xu, Hong-Li Jiang, Hui-Xuan Wu, Jun-Min Cai, Long Li, Yan-Hong Bu, Fen Xiao, Han-Dan Liang, Ying Wen, Yu-Ze Liu, Yu-Long Yin, Hou-De Zhou. Adipose Tissue Plasticity: A Comprehensive Definition and Multidimensional Insight. Biomolecules 2024; 14(10): 1223 doi: 10.3390/biom14101223
|
| 6 |
Luca Miele, Cecilia Napodano, Alfredo Cesario, Antonio De Magistris, Krizia Pocino, Umberto Basile, Gian L. Rapaccini, Antonio Gasbarrini, Antonio Grieco. COVID‐19, adaptative immune response and metabolic‐associated liver disease. Liver International 2021; 41(11): 2560 doi: 10.1111/liv.15061
|
| 7 |
Fangshuo Jiang, Ye Peng, Quancai Sun. Pesticides exposure induced obesity and its associated diseases: recent progress and challenges. Journal of Future Foods 2022; 2(2): 119 doi: 10.1016/j.jfutfo.2022.03.005
|
| 8 |
Shanshan Liu, Jialu Wang, Shujing Wu, Jingya Niu, Ruizhi Zheng, Lizhan Bie, Zhuojun Xin, Shuangyuan Wang, Hong Lin, Zhiyun Zhao, Tiange Wang, Min Xu, Jieli Lu, Yuhong Chen, Yiping Xu, Weiqing Wang, Guang Ning, Yufang Bi, Mian Li, Yu Xu. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis. Metabolism 2021; 120: 154779 doi: 10.1016/j.metabol.2021.154779
|
| 9 |
Nahum Méndez‐Sánchez, Jian‐Gao Fan, Mohamed El‐Kassas, Marcos Girala. MAFLD: A quick fact check. Liver International 2022; 42(12): 2903 doi: 10.1111/liv.15422
|
| 10 |
Xiaoqin Zhu, Chuanfei Zeng, Baoping Yu. White adipose tissue in metabolic associated fatty liver disease. Clinics and Research in Hepatology and Gastroenterology 2024; 48(5): 102336 doi: 10.1016/j.clinre.2024.102336
|
| 11 |
Chun-Liang Chen, Yu-Cheng Lin. Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target. International Journal of Molecular Sciences 2022; 23(17): 10055 doi: 10.3390/ijms231710055
|
| 12 |
Yongliang Chang, Xiawei Wu, Shengwei Lu, Jiahao Du, Yixiu Long, Yefei Zhu, Huanlong Qin. Engineered procyanidin-Fe nanoparticle alleviates intestinal inflammation through scavenging ROS and altering gut microbiome in colitis mice. Frontiers in Chemistry 2023; 11 doi: 10.3389/fchem.2023.1089775
|
| 13 |
Joselyn N. Allen, Adwitia Dey, Jingwei Cai, Jingtao Zhang, Yuan Tian, Mary Kennett, Yanling Ma, T. Jake Liang, Andrew D. Patterson, Pamela A. Hankey-Giblin. Metabolic Profiling Reveals Aggravated Non-Alcoholic Steatohepatitis in High-Fat High-Cholesterol Diet-Fed Apolipoprotein E-Deficient Mice Lacking Ron Receptor Signaling. Metabolites 2020; 10(8): 326 doi: 10.3390/metabo10080326
|
| 14 |
Gabriel Tayguara Silveira Guerreiro, Larisse Longo, Mariana Alves Fonseca, Valessa Emanoele Gabriel de Souza, Mário Reis Álvares-da-Silva. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?. Hepatology International 2021; 15(2): 380 doi: 10.1007/s12072-021-10157-y
|
| 15 |
Yiming Cao, Xiaoxue Fang, Mingyang Sun, Yegang Zhang, Mengyao Shan, Xintian Lan, Difu Zhu, Haoming Luo. Preventive and therapeutic effects of natural products and herbal extracts onnonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Phytotherapy Research 2023; 37(9): 3867 doi: 10.1002/ptr.7932
|
| 16 |
Allah Nawaz, Azhar Manzoor, Saeed Ahmed, Naveed Ahmed, Waseem Abbas, Mushtaq Ahmad Mir, Muhammad Bilal, Alisha Sheikh, Saleem Ahmad, Ishtiaq Jeelani, Takashi Nakagawa. Therapeutic approaches for chronic hepatitis C: a concise review. Frontiers in Pharmacology 2024; 14 doi: 10.3389/fphar.2023.1334160
|
| 17 |
Amr Ahmed El-Arabey, Mohnad Abdalla. GATA3 as an immunomodulator in obesity-related metabolic dysfunction associated with fatty liver disease, insulin resistance, and type 2 diabetes. Chemico-Biological Interactions 2022; 366: 110141 doi: 10.1016/j.cbi.2022.110141
|
| 18 |
Yiyuan Zheng, Dan Fang, Chaoyuan Huang, Lina Zhao, Liming Gan, Youlan Chen, Fengbin Liu. Gentiana scabra Restrains Hepatic Pro-Inflammatory Macrophages to Ameliorate Non-Alcoholic Fatty Liver Disease. Frontiers in Pharmacology 2022; 12 doi: 10.3389/fphar.2021.816032
|
| 19 |
Jawaher Alharthi, Mohammed Eslam. Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update. Journal of Clinical and Translational Hepatology 2022; 10(1): 134 doi: 10.14218/JCTH.2021.00248
|
| 20 |
Jiaxuan Wu, Jiashu Pan, Wenjun Zhou, Guang Ji, Yanqi Dang. The role of N6-methyladenosine in macrophage polarization: A novel treatment strategy for non-alcoholic steatohepatitis. Biomedicine & Pharmacotherapy 2024; 171: 116145 doi: 10.1016/j.biopha.2024.116145
|
| 21 |
Waleed Alghamdi, Mahmoud Mosli, Saleh A. Alqahtani. Gut microbiota in MAFLD: therapeutic and diagnostic implications. Therapeutic Advances in Endocrinology and Metabolism 2024; 15 doi: 10.1177/20420188241242937
|
| 22 |
Lili Yu, Wei Hong, Shen Lu, Yanrong Li, Yaya Guan, Xiaogang Weng, Zhiwei Feng. The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.780496
|
| 23 |
Mingqian Jiang, Ziyan Pan, Jacob George, Mohammed Eslam. Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD. Hepatology International 2024; doi: 10.1007/s12072-024-10721-2
|
| 24 |
Sahil Khanna, Neal S. Parikh, Lisa B. VanWagner. Fatty liver and cerebrovascular disease: plausible association and possible mechanisms. Current Opinion in Lipidology 2022; 33(1): 31 doi: 10.1097/MOL.0000000000000799
|
| 25 |
Nicolas Lanthier, Valérie Lebrun, Olivier Molendi-Coste, Nico van Rooijen, Isabelle A. Leclercq. Liver Fetuin-A at Initiation of Insulin Resistance. Metabolites 2022; 12(11): 1023 doi: 10.3390/metabo12111023
|
| 26 |
Anika Niambi Al-Shura. Metabolic Disorders and Shen in Integrative Cardiovascular Chinese Medicine. 2021; : 17 doi: 10.1016/B978-0-12-818922-1.00003-9
|
| 27 |
Amit Khurana, Umashanker Navik, Prince Allawadhi, Poonam Yadav, Ralf Weiskirchen. Spotlight on liver macrophages for halting liver disease progression and injury. Expert Opinion on Therapeutic Targets 2022; 26(8): 707 doi: 10.1080/14728222.2022.2133699
|
| 28 |
María Crespo, Ivana Nikolic, Alfonso Mora, Elena Rodríguez, Luis Leiva‐Vega, Aránzazu Pintor‐Chocano, Daniel Horrillo, Lourdes Hernández‐Cosido, Jorge L. Torres, Eva Novoa, Rubén Nogueiras, Gema Medina‐Gómez, Miguel Marcos, Magdalena Leiva, Guadalupe Sabio. Myeloid p38 activation maintains macrophage–liver crosstalk and BAT thermogenesis through IL‐12–FGF21 axis. Hepatology 2023; 77(3): 874 doi: 10.1002/hep.32581
|
| 29 |
Gao-Xin Xu, Song Wei, Chao Yu, Si-Qi Zhao, Wei-Jun Yang, Yong-Heng Feng, Chao Pan, Kun-Xing Yang, Yong Ma. Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions. Frontiers in Cell and Developmental Biology 2023; 11 doi: 10.3389/fcell.2023.1199519
|
| 30 |
Yu Jung Heo, Sung‐E Choi, Nami Lee, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, Hae Jin Kim. Visfatin exacerbates hepatic inflammation and fibrosis in a methionine‐choline‐deficient diet mouse model. Journal of Gastroenterology and Hepatology 2021; 36(9): 2592 doi: 10.1111/jgh.15465
|
| 31 |
Fang Lei, Xiao-Ming Wang, Changquan Wang, Xuewei Huang, Ye-Mao Liu, Juan-Juan Qin, Peng Zhang, Yan-Xiao Ji, Zhi-Gang She, Jingjing Cai, Huo-ping Li, Xiao-Jing Zhang, Hongliang Li. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1109673
|
| 32 |
Wei Wang, Xiu Li Guo, Xiu Ping Qiu, Yun Jie Yu, Mei Tu. Systemic immune-inflammation index mediates the association between metabolic dysfunction-associated fatty liver disease and sub-clinical carotid atherosclerosis: a mediation analysis. Frontiers in Endocrinology 2024; 15 doi: 10.3389/fendo.2024.1406793
|
| 33 |
Seongyea Jo, Sung Bum Park, Hyemin Kim, Ilkyun Im, Haneul Noh, Eun-Mi Kim, Ki Young Kim, Michael Oelgeschläger, Jong-Hoon Kim, Han-Jin Park. hiPSC-derived macrophages improve drug sensitivity and selectivity in a macrophage-incorporating organoid culture model. Biofabrication 2024; 16(3): 035021 doi: 10.1088/1758-5090/ad4c0a
|
| 34 |
Fan Yang, Ping Huang, Liandong Shi, Feng Liu, Aimei Tang, Shaohui Xu. <p>Phoenixin 14 Inhibits High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Experimental Mice</p>. Drug Design, Development and Therapy 2020; : 3865 doi: 10.2147/DDDT.S258857
|
| 35 |
Lei Liu, Changfa Wang, Shuwen Deng, Ting Yuan, Xiaoling Zhu, Yuling Deng, Yuexiang Qin, Yaqin Wang, Pingting Yang. Transition patterns of metabolic dysfunction-associated fatty liver disease status in relation to arterial stiffness progression: a health check-up cohort study. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-35733-0
|
| 36 |
Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George. Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research. Hepatology International 2024; doi: 10.1007/s12072-024-10731-0
|
| 37 |
Jawaher Alharthi, Ali Bayoumi, Khaled Thabet, Ziyan Pan, Brian S. Gloss, Olivier Latchoumanin, Mischa Lundberg, Natalie A. Twine, Duncan McLeod, Shafi Alenizi, Leon A. Adams, Martin Weltman, Thomas Berg, Christopher Liddle, Jacob George, Mohammed Eslam. A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nature Communications 2022; 13(1) doi: 10.1038/s41467-022-35158-9
|
| 38 |
Jinfan Liu, Weizhao Li, Yangping Bian, Xiaoqing Jiang, Fuyun Zhu, Fei Yin, Li Yin, Xiaomei Song, Hong Guo, Jianhui Liu. Garlic-derived exosomes regulate PFKFB3 expression to relieve liver dysfunction in high-fat diet-fed mice via macrophage-hepatocyte crosstalk. Phytomedicine 2023; 112: 154679 doi: 10.1016/j.phymed.2023.154679
|
| 39 |
Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez. Metabolic dysfunction: The silenced connection with fatty liver disease. Annals of Hepatology 2023; 28(6): 101138 doi: 10.1016/j.aohep.2023.101138
|
| 40 |
YueRuiJing Liu, JinQi Wang, Rui Jin, ZongKai Xu, XiaoYu Zhao, YunFei Li, YanChen Zhao, ZhiYuan Wu, XiuHua Guo, LiXin Tao. Associations of Metabolic Dysfunction–Associated Fatty Liver Disease With Peripheral Artery Disease: Prospective Analysis in the UK Biobank and ARIC Study. Journal of the American Heart Association 2024; 13(22) doi: 10.1161/JAHA.124.035265
|
| 41 |
Tae Kyung Yoo, Seung Wook Lee, Mi Yeon Lee, Hanna Choi, Ki-Chul Sung. Influence of MAFLD and NAFLD on arterial stiffness: A longitudinal cohort study. Nutrition, Metabolism and Cardiovascular Diseases 2024; doi: 10.1016/j.numecd.2024.03.008
|
| 42 |
Sherine Ahmed Elsherif, Ahmed Salah Alm. Role of macrophages in liver cirrhosis: fibrogenesis and resolution. Anatomy & Cell Biology 2022; 55(1): 14 doi: 10.5115/acb.21.046
|
| 43 |
Ziyan Pan, Rasha El Sharkway, Ali Bayoumi, Mayada Metwally, Brian S. Gloss, Robert Brink, David Bo Lu, Christopher Liddle, Saleh A. Alqahtani, Jun Yu, Philip J. O’Connell, Jacob George, Mohammed Eslam. Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease. Science Translational Medicine 2024; 16(741) doi: 10.1126/scitranslmed.adj0133
|
| 44 |
Jawaher Alharthi, Ziyan Pan, Brian S. Gloss, Duncan McLeod, Martin Weltman, Jacob George, Mohammed Eslam. Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism 2023; 144: 155583 doi: 10.1016/j.metabol.2023.155583
|
| 45 |
Mikkel Breinholt Kjær, Jacob George, Konstantin Kazankov, Henning Grønbæk. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. Expert Review of Gastroenterology & Hepatology 2021; 15(1): 51 doi: 10.1080/17474124.2020.1817740
|
| 46 |
Yangping Bian, Weizhao Li, Xiaoqing Jiang, Fei Yin, Li Yin, Yonglan Zhang, Hong Guo, Jianhui Liu. Garlic-derived exosomes carrying miR-396e shapes macrophage metabolic reprograming to mitigate the inflammatory response in obese adipose tissue. The Journal of Nutritional Biochemistry 2023; 113: 109249 doi: 10.1016/j.jnutbio.2022.109249
|